Journal of the Neurological Sciences最新文献

{"title":"Does engagement in cognitive activities contribute to the preservation of brain structure and connectivity in older adults?","authors":"Clara Iñesta ,&nbsp;Beatriz Bonete-López ,&nbsp;Javier Oltra-Cucarella ,&nbsp;Borja Camino-Pontes ,&nbsp;Jesús M. Cortés ,&nbsp;Juan Carlos Arango-Lasprilla ,&nbsp;Esther Sitges-Maciá","doi":"10.1016/j.jns.2025.123658","DOIUrl":"10.1016/j.jns.2025.123658","url":null,"abstract":"<div><div>Aging is associated with changes in brain structure and connectivity and decrements in certain cognitive abilities. The benefits of active lifestyles in the aging brain and cognition in older adults have been widely described. This work aimed to explore the associations between brain parameters and cognitive performance in a sample of cognitively active adults who participate in University Programs for Seniors (UPS).</div></div><div><h3>Method</h3><div>forty cognitively active adults aged 55 or older underwent a neuropsychological battery and structural magnetic resonance imaging data (MRI), diffusion tensor imaging (DTI) and functional imaging at rest (fMRI). Composite scores for four cognitive domains were calculated and the sample was then divided into two groups: a group with no low scores and a group with one or more low scores across cognitive domains.</div></div><div><h3>Results</h3><div>the results show no association between brain volume and the risk of presenting low scores, and also an absence of association between brain volume, white matter integrity, functional connectivity and cognitive performance.</div></div><div><h3>Conclusions</h3><div>Active older adults might not follow the expected brain and cognitive age-changes expected in the general population. Participation in cognitive stimulating activities might then be a possible factor for brain maintenance and determinant for increasing the cognitive reserve and cognitive impairment resistance during aging.</div></div>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"477 ","pages":"Article 123658"},"PeriodicalIF":3.2,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144878121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal inference concerns in comparing prestroke frailty and disability for outcome prediction","authors":"Paola Forti ,&nbsp;Marianna Ciani ,&nbsp;Fabiola Maioli","doi":"10.1016/j.jns.2025.123656","DOIUrl":"10.1016/j.jns.2025.123656","url":null,"abstract":"","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"477 ","pages":"Article 123656"},"PeriodicalIF":3.2,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author's Reply to “Socioeconomic and Technological Considerations in Stroke Prognosis: A Comment on Irie et al.” by Saboor et al.","authors":"Fumi Irie ,&nbsp;Ryu Matsuo ,&nbsp;Masahiro Kamouchi ,&nbsp;on behalf of the Fukuoka Stroke Registry Investigators","doi":"10.1016/j.jns.2025.123648","DOIUrl":"10.1016/j.jns.2025.123648","url":null,"abstract":"","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"476 ","pages":"Article 123648"},"PeriodicalIF":3.2,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144852367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcome measures in CIDP: A scoping and mapping review","authors":"Yusuf A. Rajabally ,&nbsp;Giorgio Maria Boggia ,&nbsp;Danielle Riley ,&nbsp;Sam Riley ,&nbsp;Judith Peatman ,&nbsp;Wim Noel ,&nbsp;Charlotte Gary ,&nbsp;Eduardo Nobile-Orazio","doi":"10.1016/j.jns.2025.123654","DOIUrl":"10.1016/j.jns.2025.123654","url":null,"abstract":"<div><h3>Background</h3><div>CIDP is a rare autoimmune disorder with varying symptom presentations. This heterogenous nature challenges standardizing disease monitoring and assessing treatment response. This study aimed to provide a comprehensive overview of clinical outcome assessments (COAs) used in CIDP.</div></div><div><h3>Methods</h3><div>A structured literature review and mapping exercise was conducted to identify COAs reported in CIDP literature published between 2010 and 2023. Supplementary searches were conducted in other relevant sources. Key publications pre-2010 were identified through handsearching or consultation with clinical experts. Clinical experts assisted with prioritization of identified COAs to those clinically relevant to CIDP.</div></div><div><h3>Results</h3><div>Overall, 2027 records were included, with 904 prioritized for COA mapping, and 524 reporting on relevant CIDP COAs. Overall, 99 different COAs were captured; the most frequent related to functional impairment, followed by humanistic burden. Three COAs were most prominent: INCAT, MRC score and I-RODS (reported in 45.6 %, 37.4 % and 29.2 % of publications respectively). Numerous CIDP biomarkers were identified; 21 publications reported on neurofilament light chain (NfL).</div></div><div><h3>Conclusion</h3><div>Substantial heterogeneity in CIDP COAs use exists. This review identified the INCAT, I-RODS, and MRC score as core measures that evaluate important, although not exhaustive, aspects of CIDP disease experience. The absence of validated CIDP biomarkers, and the heterogeneity of available COAs, may impact the assessment of CIDP treatment effectiveness. More research is needed to establish a set of comprehensive outcome measures, that are relevant to clinicians and patients with CIDP.</div></div>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"477 ","pages":"Article 123654"},"PeriodicalIF":3.2,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144863819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of MR fingerprinting in differentiating epileptogenic from non-epileptogenic cortical malformations","authors":"Ryuzaburo Kochi ,&nbsp;Ting-Yu Su ,&nbsp;Vineet Punia ,&nbsp;Spencer Morris ,&nbsp;Hiroatsu Murakami ,&nbsp;Xiaofeng Wang ,&nbsp;Ingmar Blümcke ,&nbsp;Stephen E. Jones ,&nbsp;Imad Najm ,&nbsp;Andreas V. Alexopoulos ,&nbsp;Dan Ma ,&nbsp;Zhong Irene Wang","doi":"10.1016/j.jns.2025.123651","DOIUrl":"10.1016/j.jns.2025.123651","url":null,"abstract":"<div><h3>Objective</h3><div>This study investigates the potential of magnetic resonance fingerprinting (MRF) as a non-invasive method to differentiate epileptogenic from non-epileptogenic cortical malformations.</div></div><div><h3>Methods</h3><div>Sixty-nine subjects were included: four patients with complex cortical malformations who underwent detailed pre-surgical assessments including Stereo-EEG (SEEG) and/or subsequent surgery, 17 with histopathologically confirmed FCD II, and 48 healthy controls (HC). All subjects underwent a whole-brain 3 T MRF acquisition, the reconstruction of which generated T1 and T2 relaxometry maps. A 3D ROI was created for each lesion, and ROI-based z-score normalization using HC data was performed to minimize bias from lesion location. Within-patient comparisons were performed in Cases 1–3 (each with multiple lesions); across-patient comparisons were performed in Cases 1, 2, and 4 (with radiologically diagnosed FCD II), using a reference library of histopathologically confirmed, epileptogenic FCD II lesions. The most effective MRF measures for distinguishing epileptogenic from non-epileptogenic cortical malformations were identified based on their concordance with SEEG findings, surgical location and seizure outcomes.</div></div><div><h3>Results</h3><div>In all four cases, epileptogenic malformations showed significantly increased gray-matter (GM) T1 values compared to non-epileptogenic ones, both within and across patients. In Case 4, an MRI-negative epileptogenic region exhibited elevated GM and white-matter (WM) T1 and T2 values than normal cortex, which was undetectable on conventional MRI, highlighting the sensitivity of these measures.</div></div><div><h3>Significance</h3><div>Quantitative MRF metrics, especially GM T1, hold promise as a non-invasive tool to to differentiate epileptogenic from non-epileptogenic cortical malformations. Our approach could aid SEEG implantation and surgical planning when complex/multiple cortical malformations are present.</div></div>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"477 ","pages":"Article 123651"},"PeriodicalIF":3.2,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144863821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel thrombolytic agents for acute ischemic stroke: A comprehensive review of current evidence","authors":"Julian Frederic Hotz ,&nbsp;Lisa Kaindl ,&nbsp;Stefan Krebs ,&nbsp;Sven Poli ,&nbsp;Jan Purrucker ,&nbsp;Daniel Strbian ,&nbsp;Stefan Greisenegger ,&nbsp;Marek Sykora","doi":"10.1016/j.jns.2025.123653","DOIUrl":"10.1016/j.jns.2025.123653","url":null,"abstract":"<div><div>Intravenous thrombolysis is one of the standard treatments of acute ischemic stroke. Over the last decades, alteplase (recombinant tissue type plasminogen activator, rt-PA) has been established as the main thrombolytic agent worldwide. However, the short plasma half-life of rt-PA poses logistical challenges, as it necessitates administration as a 10 % bolus followed by a 90 % infusion over one hour. These logistical difficulties, combined with the search for agents with improved efficacy and safety profiles, have spurred the development of alternative thrombolytic agents. This review summarizes current clinical evidence and emerging research on novel thrombolytic agents in acute ischemic stroke, including tenecteplase, reteplase, desmoteplase, urokinase, staphylokinase, JX10, LT3100, Ancrod, and TS23. Among these agents, tenecteplase has been most extensively studied and is already recommended for selected indications by the European Stroke Organization (ESO) and the American Heart Association and American Stroke Association (AHA/ASA). Other agents are still undergoing early clinical investigation and show different levels of potential in terms of effectiveness, safety, and ease of administration.</div></div>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"476 ","pages":"Article 123653"},"PeriodicalIF":3.2,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144827958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reduction in oral glucocorticoid use after efgartigimod initiation in clinical practice among patients with generalized myasthenia gravis","authors":"Neelam Goyal ,&nbsp;Cynthia Qi ,&nbsp;John Stone ,&nbsp;Tobias Ruck ,&nbsp;Gil I. Wolfe ,&nbsp;A. Gordon Smith ,&nbsp;Deborah Gelinas ,&nbsp;Matthew Jefferson ,&nbsp;Edward Brauer ,&nbsp;Tharun Balaji Suthagar ,&nbsp;Rohit R. Menon ,&nbsp;Mai Sato ,&nbsp;Glenn Phillips ,&nbsp;Pushpa Narayanaswami","doi":"10.1016/j.jns.2025.123652","DOIUrl":"10.1016/j.jns.2025.123652","url":null,"abstract":"<div><div>This study evaluated changes in oral glucocorticoid (GC, prednisone equivalent) use among patients with generalized myasthenia gravis (gMG) previously using chronic GCs, who initiated and continued efgartigimod for ≥12 months, identified retrospectively from a US claims database. Myasthenia Gravis Activities of Daily Living (MG-ADL) scores were retrieved from a patient support program. The primary outcome was GC average daily dose (GC ADD) assessed during the 3 months before and 3, 6, 9, and 12 months after efgartigimod initiation. Overall, 266 patients were included (mean age: 59.8 years; 45 % female). Mean (95 % CI) GC ADD was significantly reduced at 3 (14.3 [12.6, 16.0] mg/day), 6 (13.4 [11.5, 15.4] mg/day), 9 (11.6 [10.0, 13.3] mg/day), and 12 (10.2 [8.8, 11.6] mg/day) months post-efgartigimod initiation compared to baseline (17.9 [15.7, 20.1] mg/day) (<em>p</em> &lt; 0.001). At 12 months, 66 % (<em>n</em> = 176/266) reduced steroid dose. Among those, 68 % and 51 % achieved ≥50 % and ≥ 75 % ADD reduction, respectively. The proportion of patients using GC ADD of ≤5 mg/day increased from 13 % at baseline to 42 % at 12 months. Among 126 patients (47 %) who had MG-ADL scores available, there was a significant reduction from baseline in best follow-up mean (95 % CI) MG-ADL (from 7.9 [7.2, 8.5] to 3.1 [2.6, 3.6]), while mean GC ADD remained significantly reduced (<em>p</em> &lt; 0.05). Thus, in patients with gMG using chronic GCs at baseline, GC use substantially reduced following efgartigimod initiation, while retaining improved MG-ADL scores, underscoring the potential steroid-sparing effect of efgartigimod in gMG treatment.</div></div>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"477 ","pages":"Article 123652"},"PeriodicalIF":3.2,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144887282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Socioeconomic and technological considerations in stroke prognosis: A comment on Irie et al","authors":"Abdul Saboor,&nbsp;Muhammad Mustafa Khan,&nbsp;Abdullah Abdullah","doi":"10.1016/j.jns.2025.123647","DOIUrl":"10.1016/j.jns.2025.123647","url":null,"abstract":"","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"476 ","pages":"Article 123647"},"PeriodicalIF":3.2,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144827959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor: Mechanistic limitations in neutrophil-to-lymphocyte ratio as a prognostic biomarker in stroke","authors":"Haifeng Yang ,&nbsp;Junxiong Yin","doi":"10.1016/j.jns.2025.123649","DOIUrl":"10.1016/j.jns.2025.123649","url":null,"abstract":"","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"477 ","pages":"Article 123649"},"PeriodicalIF":3.2,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to letter to the editor: Mechanistic limitations in neutrophil-to-lymphocyte ratio as a prognostic biomarker in stroke.","authors":"Lucio D'Anna ,&nbsp;Gabriele Prandin","doi":"10.1016/j.jns.2025.123650","DOIUrl":"10.1016/j.jns.2025.123650","url":null,"abstract":"","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"477 ","pages":"Article 123650"},"PeriodicalIF":3.2,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}